PAF C16 Docosahexanoyl, also known as Platelet Activating Factor (PAF) with a specific fatty acid chain, is a phospholipid mediator involved in various biological processes, particularly in inflammation and immune responses. It is characterized by its unique structure, which includes a glycerol backbone, an acetyl group, and a long-chain fatty acid, specifically docosahexaenoic acid (DHA), contributing to its bioactivity. This compound is known for its potent effects on platelet aggregation, vascular permeability, and leukocyte activation. PAF C16 Docosahexanoyl plays a crucial role in cell signaling and can influence various physiological and pathological processes, including allergic reactions and cardiovascular functions. Its synthesis and degradation are tightly regulated within the body, and dysregulation can lead to various diseases. Due to its significant biological roles, PAF and its derivatives are of interest in pharmacological research, particularly for developing therapeutic agents targeting inflammatory and cardiovascular conditions.

PAF C16 Docosahexanoyl

132213-85-5: PAF C16 Docosahexanoyl, also known as Platelet Activating Factor (PAF) with a specific fatty acid chain, is a phospholipid mediator involved in various biological processes, particularly in inflammation and immune responses. It is characterized by its unique structure, which includes a glycerol backbone, an acetyl group, and a long-chain fatty acid, specifically docosahexaenoic acid (DHA), contributing to its bioactivity. This compound is known for its potent effects on platelet aggregation, vascular permeability, and leukocyte activation. PAF C16 Docosahexanoyl plays a crucial role in cell signaling and can influence various physiological and pathological processes, including allergic reactions and cardiovascular functions. Its synthesis and degradation are tightly regulated within the body, and dysregulation can lead to various diseases. Due to its significant biological roles, PAF and its derivatives are of interest in pharmacological research, particularly for developing therapeutic agents targeting inflammatory and cardiovascular conditions.

1-O-hexadecyl-2-Docosahexaenoyl-sn-glycero-3-PC

<p>1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine</p>

1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine

<p>Endogenous metabolite in urine, 1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine, linked to obesity research.</p>

CAS 132213-85-5

PAF C16 Docosahexanoyl

1-O-hexadecyl-2-Docosahexaenoyl-sn-glycero-3-PC

Ref: IN-DA0010EE

1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine

Ref: 54-OR1076454

1-O-Hexadecyl-2-O-docosahexaenoyl-sn-glycero-3-phosphorylcholine

Ref: TM-T77230